Biosimilars Expected to Take Toll on Amgen


Published on

Published in: Business, Economy & Finance
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Biosimilars Expected to Take Toll on Amgen

  1. 1. Biosimilars Expected to Take Toll on AmgenBiosimilar competition to multiple drugs is expected to reduce Amgens sales bynearly US$ 9 Billion during 2013-2020IMARC Group has recently released a new study suggesting that biosimilars willerode a significant portion of Amgens sales during 2013-2020. According to thereport entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: AFocus on the US (2011-2020)” four products from Amgen - Enbrel(Ethanercept), Epogen (Epoetin Alfa), Neupogen (Filgrastim) and Neulasta(Pegfilgrastim) are expected to face biosimilar competition during 2013-2020.The study that has done a robust analysis on 21 biopharmaceuticals facingbiosimilar competition expects the combined sales of Amgens four drugs todecline by US$ 9 Billion during 2011-2020.IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report &Forecast: A Focus on the US (2011-2020)” provides an analytical and statisticalinsight into the US biosimilar market. The study, that has been undertakenusing desk-based as well as qualitative primary research, provides and drawsupon analysis of six aspects of the US biosimilar market.Key Aspects Analyzed:Evaluating the Current Market Landscape of Biosimilars: Identification of currently marketed biosimilars and their historical performance Identifying the reasons for the slow uptake of currently marketed biosimilars Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilar Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars: Analyzing historical time series data on price, volume and sales erosion in the US & Europe
  2. 2. Analyzing previous models and assumptions on price and volume erosion caused by biosimilars Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classesEvaluating the Market Potential of Biosimilars Across Various Molecules:Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), EpoetinAlfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), InsulinLispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir),Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B(Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab(Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab(Xolair) and Natalizumab (Tysabri).Focus of the Analysis for Each Molecule: Historical background and overview Historical brand sales Patent position Competing products Biosimilars in pipeline Brand and biosimilar sales forecastEvaluating the Sales of Biosimilars across Various Indications:Indications Covered: Immunology & Inflammation, Diabetes, Oncology, BloodDisorders and Growth DeficiencyFocus of the Analysis for Each Indication: Historical brand sales Brand and biosimilar sales forecasts Indication wise breakup of moleculesEvaluating the Biosimilar Competitive Landscape:
  3. 3. Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars Identifying biosimilar manufacturers and their pipelinesTo obtain the complete report, please contact:Asia: apac@imarcgroup.comPhone: +91-120-425-6531Europe, Middle East & Africa: ema@imarcgroup.comPhone: +44-702-409-7331North & South America: america@imarcgroup.comPhone: +1-631-791-1145To know more please visit: market, biosimilar industry, biogenerics market, us biosimilar market, biosimilarmonoclonal antibodies , follow-on biologics market,